Form 4: BridgeBio Director Sells Shares After Option Exercise

BridgeBio Pharma Director Hannah Valantine exercised stock options and subsequently sold all acquired shares under a pre-arranged 10b5-1 plan.

Summary

• Director Hannah Valantine of BridgeBio Pharma, Inc. exercised 25,484 stock options for common stock at an exercise price of $48.45 per share.
• Immediately following the exercise, Valantine sold all 25,484 shares of common stock at a price of $66.07 per share.
• These transactions occurred on November 12, 2025, and were conducted pursuant to a Rule 10b5-1 plan.
• After these transactions, Valantine directly holds 7,465 shares of common stock and indirectly holds 398 shares through her spouse.
• The stock options that were exercised vested in three annual installments after October 25, 2021.

Sentiment

Score: 5

Explanation: The transaction is a pre-planned sale under a Rule 10b5-1 plan, indicating the decision to sell was made in advance and not based on recent market developments or insider information. This makes it a routine compensation-related event rather than a signal of immediate insider sentiment.

Positives

• Director exercised options, indicating value in the underlying stock at the exercise price of $48.45.
• The sale price of $66.07 per share is significantly higher than the exercise price of $48.45, indicating a profitable transaction for the director.
• The transaction was executed under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not based on recent non-public information.

Negatives

• Director sold all shares acquired from the option exercise, which results in a reduction of direct beneficial ownership.
• While under a 10b5-1 plan, the sale still represents a director reducing their direct stake in the company.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Indirect beneficial ownership of 398 shares by spouse.

Stakeholder Impact

• Shareholders: May interpret the sale as a routine compensation-related transaction, given it was executed under a Rule 10b5-1 plan, rather than a discretionary sale based on current market conditions.

Key Dates

Recommendation

This Form 4 reports a pre-planned insider transaction under a Rule 10b5-1 plan, where a director exercised stock options and immediately sold the acquired shares. Such transactions are typically for liquidity or tax purposes and are scheduled in advance, meaning they do not reflect a current discretionary decision based on recent company performance or outlook. Therefore, this filing alone does not provide sufficient new information to warrant a change in investment recommendation.

Keywords

BridgeBio Pharma, BBIO, insider trading, stock option exercise, share sale, director transaction, Form 4, 10b5-1 plan